Duration of Virus Shedding After Trivalent Intranasal Live Attenuated Influenza Vaccination in Adults

@article{Talbot2005DurationOV,
  title={Duration of Virus Shedding After Trivalent Intranasal Live Attenuated Influenza Vaccination in Adults},
  author={Thomas R. Talbot and Deidre D Crocker and Jody Peters and Jennifer K Doersam and Mine R. Ikizler and Edith C. Sannella and Peter Wright and Kathryn M. Edwards},
  journal={Infection Control \&\#x0026; Hospital Epidemiology},
  year={2005},
  volume={26},
  pages={494 - 500}
}
Abstract Objective: To characterize the probability and duration of viral shedding among adults given trivalent live attenuated influenza vaccine (LATV). Design: Prospective surveillance study. Methods: Nasal wash samples were collected from adult volunteers at baseline and on days 3, 7, and 10 and between days 17 and 21 following intranasal LAIV vaccination. The presence, titer, and identification of each specific strain of influenza virus shed were determined by standard methodology. Results… 
View on Cambridge Press
mc.vanderbilt.edu
60 Citations
Highly Influential Citations
2
Background Citations
19
Methods Citations
1
Results Citations
4

60 Citations

Citation Type

Citation Type

Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age.
Kinetics of viral shedding and immune responses in adults following administration of cold-adapted influenza vaccine.
Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings
TLDR
Despite the small sample size, the results indicate that LAIV vaccine strains are detectable during the week after LAIV, mainly in younger individuals and vaccinees with CF.
Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
Live Attenuated Influenza Vaccine (FluMist®; Fluenz™)
TLDR
Intranasal LAIV seasonal influenza vaccine is effective and well tolerated in children, adolescents and adults, and LAIV was more effective than TIV inChildren, although this advantage was not seen in adults.
Safety, immunogenicity and shedding of LAIV4 in HIV-infected and uninfected children.
Duration of Influenza A Virus Shedding in Hospitalized Patients and Implications for Infection Control
TLDR
Hospitalized patients with influenza A virus infection can shed detectable virus beyond the 5- to 7-day period traditionally considered the duration of infectivity, and additional research is needed to assess whether prolonging theduration of patient isolation is warranted to prevent nosocomial outbreaks during the influenza season.
Pre‐existing influenza‐specific nasal IgA or nasal viral infection does not affect live attenuated influenza vaccine immunogenicity in children
TLDR
Overall, it is observed that there is no effect of pre‐existing influenza‐specific nasal antibody levels on immunogenicity, supporting annual immunization with LAIV in children.
Seasonal influenza vaccines.
TLDR
Study of the safety of LAIV among young children suggest an increased risk of wheezing in some young children, and the vaccine is not recommended for children younger than 2 years old, ages 2-4 old with a history of recurrent wheazing or reactive airways disease, or older persons who have any medical condition that confers an increasedrisk of influenza-related complications.
Pneumococcal colonization impairs nasal and lung mucosal immune responses to Live Attenuated Influenza Vaccination in adults
TLDR
It is indicated that TIV and LAIV elicit differential immunity to adults and that LAIV immunogenicity is diminished by the nasal presence of S. pneumoniae, and this important confounder should be considered when assessing LAIV efficacy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 39 REFERENCES
The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children.
TLDR
A live attenuated, cold-adapted, trivalent influenzavirus vaccine was safe, immunogenic, and effective against influenza A(H3N2) and B in healthy children.
Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine.
Current status of live attenuated influenza virus vaccine in the US.
Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children.
TLDR
If relatively healthy HIV-infected children become exposed to LAIV inadvertently, then serious adverse outcomes would not be expected to occur frequently.
Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children.
Immune correlates of protection against influenza in the human challenge model.
TLDR
Results of studies of antiviral or vaccine approaches in the challenge model have been predictive of efficacy in the real world, but it is recognized that the model does not reproduce naturally acquired illness well and both viral shedding and symptoms in the challenged model are mostly restricted to the upper respiratory tract.
Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults.
TLDR
Both simultaneous and sequential inoculations of susceptible adults with CR influenza vaccine viruses result in reduced viral shedding and serum antibody responses.
Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults.
TLDR
The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events.
Use of influenza A virus vaccines in seronegative children: live cold-adapted versus inactivated whole virus.
TLDR
Protection against infection and symptomatic illness in children inoculated with ca H1N1, despite its failure to stimulate high levels of hemagglutinin-inhibiting antibody is suggested.
Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy, working adults: a randomized controlled trial.
TLDR
Intranasal trivalent LAIV vaccine was safe and effective in healthy, working adults in a year in which a drifted influenza A virus predominated, suggesting that LAIV provided substantial cross-protection against this variant influenza Airus strain.
...
1
2
3
4
...